Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05277402 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start date: February 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors. Study drug ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody) which is indicated for the treatment of patients across a number of indications. The treatment strategy of using anti-PD 1 therapy combined with anti-CTLA-4 therapy is to explore the potential of combination checkpoint inhibition regimens for the enhanced antitumor efficacy results.

NCT ID: NCT03833427 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.

NCT ID: NCT02665416 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Start date: January 25, 2016
Phase: Phase 1
Study type: Interventional

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.